Status:
COMPLETED
PrEP at a Syringe Services Program
Lead Sponsor:
University of Miami
Collaborating Sponsors:
Gilead Sciences
Conditions:
Hiv
Substance Use Disorders
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to see if providing participants with pre-exposure prophylaxis (PrEP) medicine right away at the IDEA Exchange will help participants remain in HIV negative.
Eligibility Criteria
Inclusion
- over the age of 18
- speak either English or Spanish
- ability to provide informed consent
- currently enrolled in the syringe services program
- have a negative HIV rapid test result
- estimated creatinine clearance \> 30 ml/minute
Exclusion
- do not meet the above criteria of inclusion
- decline to participate
- test positive for HIV via rapid test
- are pregnant or plan on becoming pregnant
- have symptoms acute HIV.
- Any other comorbidities that at the discretion of the investigator would prevent the participant from participating in the study.
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 11 2024
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04782180
Start Date
February 1 2022
End Date
November 11 2024
Last Update
December 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Miami
Miami, Florida, United States, 33136